DPP-IV抑制剂、噻唑烷二酮和磺脲类对2型糖尿病患者骨质疏松的影响:基于人群的队列研究
该基于韩国国民健康保险理赔数据库的人群队列研究,纳入381,404例50-99岁2型糖尿病患者,比较DPP-IV抑制剂、噻唑烷二酮和磺脲类与骨质疏松的关联。结果显示,与磺脲类相比,DPP-IV抑制剂不增加骨质疏松风险(HR 0.97;95%CI 0.94-1.00),而噻唑烷二酮与骨质疏松风险轻度增加相关(HR 1.13;95%CI 1.06-1.20)。
要点
- 与磺脲类相比,DPP-IV抑制剂不增加2型糖尿病患者骨质疏松风险。
- 噻唑烷二酮类与骨质疏松风险轻度增加相关(HR 1.13;95%CI 1.06-1.20)。
- 亚组分析中吡格列酮和格列本脲风险较高,沙格列汀和西格列汀风险较低。
核心结论
- 在2型糖尿病患者中,与磺脲类相比,DPP-IV抑制剂不增加骨质疏松风险,而噻唑烷二酮与骨质疏松风险轻度增加相关。
研究设计与样本
- 基于韩国国民健康保险理赔数据库的人群队列研究,纳入2013-2015年处方DPP-IV抑制剂、噻唑烷二酮或磺脲类的50-99岁2型糖尿病患者,经逆概率治疗加权后分析381,404例。
主要发现
- 多变量调整分析中,DPP-IV抑制剂组骨质疏松风险与磺脲类组无显著差异(HR 0.97;95%CI 0.94-1.00)。
- 噻唑烷二酮组骨质疏松风险高于磺脲类组(HR 1.13;95%CI 1.06-1.20)。
- 亚组分析中,吡格列酮组HR为1.14(95%CI 1.06-1.23),格列本脲组HR为1.39(95%CI 1.09-1.77)。
- DPP-IV抑制剂组中,沙格列汀HR为0.93(95%CI 0.87-0.99),西格列汀HR为0.93(95%CI 0.89-0.97)。
关键数值与推荐
- 骨质疏松风险比较采用Cox比例风险模型,经逆概率治疗加权后分析。
临床怎么用
- 在2型糖尿病合并骨质疏松风险的患者中,DPP-IV抑制剂相较磺脲类不增加骨质疏松风险,可作为考虑选项。
- 使用噻唑烷二酮类(尤其吡格列酮)时需关注骨质疏松风险,必要时评估骨健康。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The population-based cohort study used the Korean National Health Insurance claims database to evaluate the effect of anti-diabetic drugs on osteoporosis. The use of DPP-IV inhibitors does not increase the risk of osteoporosis compared with the use of sulfonylureas in patients with type 2 diabetes mellitus, while a weak association was found between thiazolidinediones and increased risk of osteoporosis. PURPOSE: The current study aimed to evaluate the effect of dipeptidyl peptidase IV inhibitors (DPP-IVi), thiazolidinedione (TZD), and sulfonylurea (SU) on osteoporosis in patients with type 2 diabetes. METHODS: A population-based cohort study was conducted in the Republic of Korea using the Korean National Health Insurance claims database. Data from 2012 to 2017 for patients of 50-99 years of age who were prescribed DPP-IVi, TZD, or SU during 2013-2015 were extracted from the database. Based on pre-defined criteria, a total of 381,404 patients were analyzed after inverse probability of treatment weighting. The association between the study drugs and osteoporosis was estimated using Cox proportional hazards models. Data of 220,166 patients who were prescribed DPP-IVi, 18,630 who were prescribed TZD, and 142,608 patients who were prescribed SU were set. RESULTS: In the multivariate-adjusted analysis, the hazard ratio (HR) of osteoporosis in the DPP-IVi group was not significantly different from that of the SU group (HR: 0.97; 95% confidence interval (CI) 0.94-1.00), whereas the HR of osteoporosis in the TZD group was higher (HR: 1.13; 95% CI 1.06-1.20). In the subgroup analysis, the HRs of osteoporosis were higher with pioglitazone (HR: 1.14; 95% CI 1.06-1.23) in the TZD group and with glibenclamides (HR: 1.39; 95% CI 1.09-1.77) in the SU group, whereas drugs with lower HR in the DPP-IVi group were saxagliptin (HR: 0.93; 95% CI 0.87-0.99) and sitagliptin (HR: 0.93; 95% CI 0.89-0.97). CONCLUSION: DPP-IV inhibitors do not increase the risk of osteoporosis compared with sulfonylureas in patients with type 2 diabetes mellitus, while a weak association was found between thiazolidinediones and increased risk of osteoporosis.
引用
- Yang BR, Cha SH, Lee KE, et al. Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study. Osteoporos Int. 2021. PMID: 33594487. doi:10.1007/s00198-020-05801-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。